Premium
DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040
Author(s) -
Hill George J.,
Moss Scot E.,
Golomb Frederick M.,
Grage Theodor B.,
Fletcher William S.,
Minton John P.,
Krementz Edward T.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810601)47:11<2556::aid-cncr2820471107>3.0.co;2-j
Subject(s) - medicine , adjuvant , cog , dacarbazine , lomustine , melanoma , protocol (science) , oncology , adjuvant therapy , cancer research , chemotherapy , pathology , vincristine , cyclophosphamide , alternative medicine , artificial intelligence , computer science
A prospectively randomized study of postoperative chemotherapy with dimethyl triazeno imidazole carboxamide (DTIC) was conducted by the Central Oncology Group from 1972 until 1976. Of 174 patients operated upon for melanoma and entered into the study, 87 were randomly selected to receive DTIC, four courses in 12 months, at 4.5 mg/kg/d × 10. One‐hundred‐sixty‐five (95%) of the cases were evaluable, including 40 high risk Stage I, 96 Stage II, and 29 Stage III cases. At a median follow‐up period of 2.5 years, the control group had a better median disease‐free interval (40 weeks vs. 73 weeks), median survival time (103 weeks vs. 133 weeks), and percentage of patients living free of disease (28% vs. 44%) than the DTIC‐treated group. While disease‐free interval appeared to be improved in the 25% of patients on DTIC therapy who developed thrombocytopenia, the overall effect of postoperative DTIC therapy was apparently not beneficial ( P < 0.05).